Abstract: The present invention enables random access which does not cause a load on a mobile station apparatus in an Advanced-EUTRA system.

Abstract: In a camera module (51), a lid glass (15) protrudes from a sensor cover (14) toward an image pickup lens (1), and a base section (9) includes an overhanging part (9b) overhanging in such a manner as to cover part of the lid glass (15).

Abstract: Aspects of the present invention are related to systems and methods for automatically determining the content boundaries in a digital image. A gradient field may be generated using an edge detector, and the gradient field may be thresholded, by magnitude, to retain strong edges. The resulting localized edge positions may be projected onto a first direction and a second direction to form two projection histograms. The projection histograms may be analyzed to determine the boundaries of the image content. Corners of a cropping rectangle may be computed, and the digital image may be cropped according to the content boundaries.

Abstract: In a light emitting section, a phosphor layer including a first phosphor particle which receives excitation light and emits fluorescence with a first peak wavelength and a phosphor layer including a second phosphor particle which receives the excitation light and emits fluorescence with a second peak wavelength are stacked. In the light emitting section, when an upper surface is a surface from which illumination light is mostly emitted, the illumination light including the fluorescence emitted from the first phosphor particle and the fluorescence emitted from the second phosphor particle, a reflective member to reduce leakage of fluorescence is provided on a side surface of the light emitting section.

Abstract: The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.

Abstract: A display device performs display with a dot inversion driving method wherein, during a prescribed period of time between one driving period in which all of the scanning signal lines are scanned and a next driving period, an idle period that is longer in duration than each driving period is provided during which potentials of the plurality of data signal lines are kept constant, and during the idle period, the driving power control unit lowers a driving power of the signal line driver circuit, and wherein the signal line driver circuit outputs the data signals to the respective data signal lines during the driving period, and during the idle period, the signal line driver circuit sets an output thereof to the respective data signal lines to one of a high impedance state and a ground potential, such that the plurality of data signal lines have a constant potential.

Abstract: For aperiodic reporting of CSI, nCQI ref is four, and a subframe n?nCQI ref corresponds to a valid subframe. A subframe that satisfies a criteria including at least a criterion (i) is regarded as being valid. In the criterion (i), in a case where third information for a radio frame is detected, an UL-DL configuration for the radio frame is given by the third information for the radio frame, and in a case where the third information for the radio frame is not detected, the UL-DL configuration for the radio frame is given by first information. The criterion (i) stipulates that the subframe is a subframe indicated as a DL subframe or a special subframe by the UL-DL configuration for the radio frame. In a case where a subframe n?4 is not a valid subframe for aperiodic reporting of channel state information, the reporting of the CSI is omitted in the subframe n.

Abstract: The present disclosure provides a method for repetitive transmission of a physical control channel. The method comprises: transmitting the physical control channel in a number of Control Channel Elements (CCEs) of each subframe in a set of subframes for repetitive transmission of the physical control channel. The present disclosure also provides a method for receiving a physical control channel, a base station and a User Equipment.

Abstract: A DC-DC converter includes a transformer, a switching circuit provided on the primary side of the transformer, and a rectifier circuit provided on the secondary side of the transformer. The rectifier circuit includes a first rectifier part that is serially connected body of a first transistor and a second transistor having a first electrode connected to a second electrode of the first transistor. The first and second transistors each include a parasitic diode connected forward between the second and first electrode, and the withstanding voltage between the first and second electrodes of the first transistor is higher than the withstanding voltage between the first and second electrodes of the second transistor.

Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Abstract: A terminal apparatus according to one aspect of the present invention constitutes and reports an amount-of-transmission-buffer report to be notified to a base station apparatus, based on first transmission data to the base station apparatus, which is prepared in a transmission buffer of the terminal apparatus itself, second transmission data for device-to-device data communication, and a priority level of each piece of transmission data.

Abstract: An active matrix substrate (12A) of a liquid crystal display device (10) includes: drive electrodes (32A, 32B) a pair of which are arranged in each pixel; pixel electrodes (36) each of which is provided in each pixel; first switching elements (34A) each of which is connected to one of the pair of drive electrode (32A); second switching elements (34B) each of which is connected to the other drive electrode (32B); third switching elements (34C) connected to the pixel electrodes (36); first source lines (30A) connected to the group of the first switching elements (34); second source lines (30B) connected to the group of the second switching elements (34B); third source lines (30C) connected to the group of the third switching elements (30C); and a plurality of gate lines (28).

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: According to the present invention, there is provided a terminal device that transmits a signal to a base station apparatus through uplink, the terminal device including: an information generation unit that considers a priority level for multiple MAC control elements in the logical channel prioritization procedure for the uplink, in a case where initial transmission is performed, in which at least a first MAC control element and a second MAC control element are included in the multiple MAC control elements, in which the first MAC control element provides the base station apparatus with information on an amount of first data available for transmission within a first buffer for the uplink, in which the second MAC control element provides the base station apparatus with information on amount of second data available for transmission within a second buffer for a first link that is used for communication between the terminal device and a different terminal device, and in which the first MAC control element has a h

Abstract: In a switching power supply circuit (1A) of the invention, a low-voltage node capacitor (5) is connected between a primary-side low-voltage stable potential node (LN1) and a secondary-side low-voltage stable potential node (LN2), and a high-voltage node capacitor (4) is connected between a primary-side high-voltage stable potential node (HN1) and an anode of a rectifier element (31). Thereby, it is possible to provide the switching power supply circuit which achieves, with a simple configuration, both of noise reduction and potential stabilization of stable potential nodes.

Abstract: The present invention provides a vapor deposition apparatus, a vapor deposition method, and a method for producing an organic electroluminescent element which can control the vapor deposition rate on the substrate in the entire vapor deposition region with excellent precision. The vapor deposition apparatus of the present invention that forms a film on a substrate includes a first thickness monitor; and a vapor deposition unit including a vapor deposition source, the apparatus being configured to perform vapor deposition while controlling the distance between a portion of the vapor deposition source designed to eject a vaporized material and a surface of the substrate on which the vapor deposition is performed, based on a measurement result from the first thickness monitor.

Abstract: An agitation unit includes an agitation tank to which a liquid is supplied and an agitation member which agitates the liquid supplied to the agitation tank. The agitation tank has an area of opening in a horizontal direction decreasing in a downward direction.

Abstract: The light control film includes a base material with transparency and a light control layer that is provided on a side of a surface which faces a display surface of a display panel in the base material, has a light shielding portion which is formed on one surface of the base material, and controls an emission direction of light by diffusing light which is emitted from the display surface, in which the light control layer includes a light emission end surface that contacts with the base material, a light incident end surface that faces the light emission end surface and has a larger area than an area of the light emission end surface, and a reflection surface that contacts with the light emission end surface and the light incident end surface and reflects light which is incident from the light incident end surface, a height from the light incident end surface to the light emission end surface is larger than a layer thickness of the light shielding portion, and the reflection surface reflects light to allocate

Abstract: In a method of performing dilution of a droplet in an EWOD device, a parent droplet is provided on an electrode array of the EWOD device, wherein the parent droplet has a first concentration of a species. A diluent droplet also is provided on the electrode array of the EWOD device. The method includes controlling actuation voltages applied to the electrode array of the EWOD device to join the parent droplet and the diluent droplet into a product droplet having a diluted second concentration of the species different from the first concentration in the parent droplet. The actuation voltages then are controlled to split the product droplet into one or more daughter droplets having the second concentration of the species. A dilution ratio may be calibrated based on the volumes of the droplets. Serial dilution steps may be performed to generate daughter droplets of different species concentrations at each step.

Abstract: The present invention relates to novel N-substituted azetidine derivatives < of the formula (I); wherein SERMF is a Selective Estrogen Receptor Modilator fragment; X is no atom, O, S, CH2, carbonyl, N—R5; R1 is H, (C1-8)alkyl, (C3-8)cycloalkyl, (C3-6)heterocycloalkyl, (C2-6)alkenyl, (C2-6)alkynyl, (C1-4)alkylcarbonyl, (C1-4)alkoxy(C2-4)alkyl, (C3-6)cycloalkyl(C1-3)-alkyl, (C3-6)heterocycloalkyl(C1-3)alkyl, each independently optionally substituted with one or more halogen, nitrile, hydroxyl or (C1-2)alkyl; R5 is H, (C1-3)alkyl, optionally substituted with one or more fluorine; R17, R18 and R19 are independently of each other H, fluorine, nitrile or (C1-3)-alkyl, optionally substituted with one or more fluorine; or a prodrug, isotopically-labelled derivative or pharmaceutically acceptable salt thereof, > to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the prevention or treatment of ovulatory dysfunction, uterine cancer, endometrium can